What is the clinical evidence from this study?

Study design: Review. Population: Non-valvular atrial fibrillation. Intervention: Percutaneous Left Atrial Appendage Occlusion vs. Oral Anticoagulant Therapy.

What does this research mean for the field?

Left atrial appendage occlusion is a viable non-pharmacological option for preventing cardioembolic events in patients with non-valvular atrial fibrillation who have a contraindication to oral anticoagulants. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

September 28, 2023European Cardiology ReviewOpen Access

Percutaneous Left Atrial Appendage Occlusion: What the Practising Physician Should Know

View Full Paper

Ask AI

Bookmark

Key result

LAAO provides a non-pharmacological option to prevent cardioembolic events in NVAF patients with OAC contraindications.

Why the study?

Many patients with non-valvular AF cannot receive oral anticoagulant therapy due to bleeding or high bleeding risk, driving exponentially growing demand for left atrial appendage occlusion.

Does percutaneous left atrial appendage occlusion prevent cardioembolic events in patients with non-valvular AF and contraindications to oral anticoagulant therapy?

Structured PICO

Does percutaneous left atrial appendage occlusion prevent cardioembolic events in patients with non-valvular AF and contraindications to oral anticoagulant therapy?

Population

Patients with non-valvular atrial fibrillation (NVAF) and a high risk of bleeding or contraindications to oral anticoagulant therapy

Intervention

Percutaneous Left Atrial Appendage Occlusion (LAAO)

Percutaneous LAAO provides an effective mechanical alternative for stroke prevention in patients with non-valvular AF who cannot tolerate long-term oral anticoagulation.

Limitations

Lack of randomized trials comparing LAAO in patients who cannot tolerate even short-term anticoagulation
Optimal post-LAAO antithrombotic therapy remains unclear
Inability of the procedure to modify residual risk from concomitant atrial cardiomyopathy or systemic prothrombotic state

Implication

Supports LAAO consideration in non-valvular AF with OAC contraindications; leaves open need for randomized confirmation.

Abstract

Non-valvular AF is a common clinical condition associated with an increased risk of thromboembolic complications. As a consequence, oral anticoagulant therapy (OAT) is the cornerstone of non-valvular AF management. Despite the well-established efficacy of OAT, many patients cannot receive this preventive therapy due to bleeding or a high risk of bleeding. The fact that more than 90% of thrombi are formed in the left atrial appendage has led to the development of alternative methods to reduce the embolic risk. Left atrial appendage occlusion (LAAO) is a non-pharmacological option for preventing cardioembolic events in patients with non-valvular AF with a contraindication to OAT. The demand for LAAO procedures is growing exponentially and clinicians should consider this alternative option when managing patients with a contraindication to OAT. This review summarises the current thinking about LAAO.

Discussion

No takes yet. Share an insight, caveat, or question.

Figures from the paper

Published by European Cardiology Review · CC BY-NC

Cite This Study

Merella et al. (2023) conducted a review in Non-valvular atrial fibrillation. Percutaneous Left Atrial Appendage Occlusion vs. Oral Anticoagulant Therapy was evaluated. Left atrial appendage occlusion is a non-pharmacological option for preventing cardioembolic events in patients with non-valvular atrial fibrillation and a contraindication to oral anticoagulants.

synapsesocial.com/papers/6a12bebf86514ddae6c07866 https://doi.org/10.15420/ecr.2023.18